

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1 – 14 (canceled)

Claim 15 (new): An propellant-free inhalable solution or suspension which comprises as an active substance a salt of tiotropium combined with a second active substance which is one or more NK₁-receptor antagonists, in a solvent selected from among water on its own or a mixture of water and ethanol, wherein the active substances may be formulated together and combined with the solvent or the active substances may be separately formulated and then the separate formulations combined with the solvent.


Claim 16 (new): The propellant-free inhalable solution or suspension as recited in Claim 15 wherein the solvent is a mixture of water and ethanol, in which the relative proportion of ethanol is up to 70 percent by volume.

Claim 17 (new): The propellant-free inhalable solution or suspension as recited in Claim 15 wherein the salt of tiotropium is the chloride, bromide, iodide, methane sulphonate or paratoluene sulphonate salt.

Claim 18 (new): The propellant-free inhalable solution or suspension as recited in Claim 17 wherein the salt of tiotropium is the bromide salt.



Claim 19 (new): The propellant-free inhalable solution or suspension as recited in Claim 15 wherein the NK₁-receptor antagonist is selected from among BIIF 1149, CP-122721, FK-888, NKP 608C, NKP 608A, CGP 60829, SR 48968(Saredutant), SR 140333 (Nolpitantium besilate/chloride), LY 303 870 (Lanepitant), MEN-11420 (Nepadutant), SB 223412, MDL-105172A, MDL-103896, MEN-11149, MEN-11467, DNK 333A, SR-144190, YM-49244, YM-44778, ZM-274773, MEN-10930, S-19752,

Neuronorm, YM-35375, DA-5018, MK-869, L-754030, CJ-11974, L-758298, DNK-33A, 6b-I, CJ-11974, TAK-637, GR 205171, N-[2-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-2-{4-[(3-hydroxy-propyl)-methyl-amino]-piperidin-1-yl}-N-methyl-2-phenyl-acetamide, N-[2-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-2-[4-(2-hydroxy-1-hydroxymethyl-ethylamino)-piperidin-1-yl]-N-methyl-2-phenylacetamide, BIIM1310 N-[2-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-2-[4-(cyclopropylmethyl-methyl-amino)-piperidin-1-yl]-N-methyl-2-phenyl-acetamide, N-[2-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-2-{4-[(2-hydroxy-ethyl)-(3-hydroxy-propyl)-amino]-piperidin-1-yl}-N-methyl-2-phenyl-acetamide, N-[2-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-2-{4-[cyclopropylmethyl-(3-hydroxy-propyl)-amino]-piperidin-1-yl}-N-methyl-2-phenyl-acetamide and the arylglycinamide derivatives of general formula 3



wherein

R¹ and R² together with the N to which they are bound form a ring of formula




wherein r and s are 2 or 3;

R⁶ denotes H, -C₁-C₅-alkyl, C₃-C₅-alkenyl, propynyl, hydroxy(C₂-C₄)alkyl, methoxy(C₂-C₄)alkyl, di(C₁-C₃)alkylamino(C₂-C₄)alkyl, amino(C₂-C₄)alkyl, amino, di(C₁-C₃)alkylamino, monofluoro to perfluoro(C₁-C₂)alkyl, N-methylpiperidinyl, pyridyl, pyrimidinyl, pyrazinyl or pyridazinyl,

R⁷ has one of the meanings (a) to (d),

- (a) hydroxy
- (b) 4-piperidinopiperidyl,
- (c)




wherein R¹⁶ and R¹⁷ independently of each other denote H, (C₁-C₄)alkyl, (C₃-C₆)cycloalkyl, hydroxy(C₂-C₄)alkyl, dihydroxy(C₂-C₄)alkyl, (C₁-C₃)alkoxy(C₂-C₄)alkyl, phenyl(C₁-C₄)alkyl or di(C₁-C₃)alkylamino(C₂-C₄)alkyl,

R⁸ denotes H, optionally in the form of the enantiomers and mixtures of enantiomers thereof, optionally in the form of the racemates thereof.

Claim 20 (new): The propellant-free inhalable solution or suspension as recited in Claim 19 wherein the NK₁-receptor antagonist is selected from BIIF 1149, CP-122721, CGP 60829, MK-869, CJ-11974, GR 205171, N-[2-(3,5-bis-trifluoromethyl-


phenyl)-ethyl]-2-{4-[(3-hydroxy-propyl)-methyl-amino]-piperidin-1-yl}-N-methyl-2-phenyl-acetamide, N-[2-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-2-[4-(2-hydroxy-1-hydroxymethyl-ethylamino)-piperidin-1-yl]-N-methyl-2-phenylacetamide, BIIM1310 N-[2-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-2-[4-(cyclopropylmethyl-methyl-amino)-piperidin-1-yl]-N-methyl-2-phenyl-acetamide, N-[2-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-2-{4-[(2-hydroxy-ethyl)-(3-hydroxy-propyl)-amino]-piperidin-1-yl}-N-methyl-2-phenyl-acetamide, N-[2-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-2-{4-[cyclopropylmethyl-(3-hydroxy-propyl)-amino]-piperidin-1-yl}-N-methyl-2-phenyl-acetamide and the arylglycinamide derivatives of general formula 3, wherein

R¹ and R² together with the N to which they are bound form a ring of formula



wherein s is 2 or 3;

R⁷ denotes a group



wherein R¹⁶ and R¹⁷ independently of each other denote H, (C₁-C₄)alkyl, (C₃-C₆)cycloalkyl, hydroxy(C₂-C₄)alkyl, dihydroxy(C₂-C₄)alkyl, (C₁-C₃)alkoxy(C₂-C₄)alkyl, phenyl(C₁-C₄)alkyl or di(C₁-C₃)alkylamino(C₂-C₄)alkyl,

R⁸ denotes H,

optionally in the form of the enantiomers and mixtures of enantiomers thereof and optionally in the form of the racemates thereof.

Claim 21(new): The propellant-free inhalable solution or suspension as recited in Claim 20 wherein the NK₁-receptor antagonist is selected from (S)-N-[2-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-2-[4-(2-hydroxy-1-hydroxymethyl-ethylamino)-piperidin-1-yl]-N-methyl-2-phenylacetamide or an acid addition salt thereof.

Claim 22 (new): The propellant-free inhalable solution or suspension as recited in Claim 15 wherein the weight ratio of the tiotropium salt to the NK₁-receptor antagonist is about 1:300 to about 50:1.

Claim 23 (new): The propellant-free inhalable solution or suspension in Claim 22 wherein the weight ratio of the tiotropium salt to the NK₁-receptor antagonist is about 1:250 to about 40:1.

Claim 24 (new): A method for treatment of asthma in a warm-blooded animal which comprises administering a therapeutically effective amount of a propellant-free inhalable solution or suspension as recited in claim 15.

Claim 25 (new): A method for treatment of chronic obstructive pulmonary disease in a warm-blooded animal which comprises administering a therapeutically effective amount of a propellant-free inhalable solution or suspension as recited in claim 15.

Claim 26 (new): The method for treatment of chronic obstructive pulmonary disease in a warm-blooded animal as recited in claim 25 wherein the tiotropium salt and the NK₁-receptor antagonist are present in separate formulations.